A low-immunogenic polygonatum sibiricum lectin modified protein for preventing and treating coronavirus infection, and its preparation method and use

By genetically modifying Polygonatin PCL, the low immunogenic mutant M4 was obtained, which solved the problem of activation of Polygonatin lectin protein in the body, achieved efficient blockade and neutralization of the novel coronavirus, and provided a low immunity A prototypical, highly effective antiviral drugs.

CN118754959BActive Publication Date: 2024-11-08SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411238416.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-05
Publication Date
2024-11-08
Estimated Expiration
2044-09-05

AI Technical Summary

Technical Problem

The existing polining lectin protein has high immunogenicity when used as an antiviral drug, which leads to activate the body's autoimmune response in the body, affects the efficacy, and is difficult to effectively block the invasion of the coronavirus.

Method used

By genetically modifying Polygonatin PCL, the low immunogenic mutant M4 was obtained, and the proline in its amino acid sequence was replaced as serine. Mutation sites targeting T cell epitopes were designed. After combining mannose, a highly efficient binding was prepared. S protein sugar chain and inhibitory activity of Polygonatin lectin engineered protein M4.

Benefits of technology

Polygonatin lectin engineered protein M4 significantly reduces immunogenicity, enhances the ability to block the novel coronavirus, effectively neutralizes the novel coronavirus and its Delta mutant strain, reduces the production of inflammatory factors, and provides a low immunogenicity. Highly effective antiviral drug candidates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118754959B_ABST
    Figure CN118754959B_ABST
Patent Text Reader

Abstract

The present invention provides a low-immunogenicity Polygonatum sibiricum lectin modified protein for preventing and treating coronavirus infection, and a preparation method and use thereof, which belong to the field of biomedical technology. The present invention provides a Polygonatum sibiricum lectin modified protein M4, whose amino acid sequence is shown in SEQ ID NO:6; the nucleotide sequence is shown in SEQ ID NO:10. The present invention also provides a preparation method and use of the Polygonatum sibiricum lectin modified protein M4. The modified protein of the present invention can effectively block the infection of the new coronavirus pseudovirus and its Delta mutant strain to HEK293T‑ACE2 cells, and prevent the infection of the new coronavirus; it has antiviral and low immunogenicity, and provides a candidate possibility for the protein to be designed to develop a broad-spectrum inhibitor or drug against coronavirus infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a modified polygonatum lectin protein and a preparation method and application thereof, belonging to the technical field of biomedicine. Background Art

[0002] The immune escape and drug off-target caused by the high glycosylation of the virus surface S protein are obstacles and challenges faced by the development of SARS-CoV-2 vaccines and other drugs. Blocking the recognition and binding of the virus and host cells by binding and blocking the sugar chains of the virus surface glycoprotein may be an effective strategy to block and prevent viral infection. Therefore, infection blocking targeting sugar chains may become a new breakthrough in drug development.

[0003] Lectins are a class of non-immune proteins or glycoproteins that specifically recognize and bind to sugars and their complexes (Damme, EJMV, Peumans, WJ, Barre, A.&Rougé, P. Plant Lectins: A Composite of Several Distinct Families of Structurally and Evolutionary Related Proteins with Diverse Biological Roles. Critical Reviews in Plant Sciences17, 575-692). They can recognize and bind to specific sugar structures, and thus play an important role in cell recognition and adhesion reactions. In immune responses, lectins activate the body's immune defense mechanism by recognizing sugar patterns on the surface of pathogenic microorganisms. However, the immunogenicity of lectins mainly involves the immune response that they may induce when used as therapeutic agents or research tools.

[0004] Polygonatum cyrtonema agglutinin ( Polygonatum cyrtonemaLectin (PCL) is a lectin that specifically recognizes and binds mannose and sialic acid, which was isolated by the inventor from traditional Chinese herbal medicine (An, J. et al. Anti-HIV I / II activity and molecular cloning of a novel mannose / sialic acid-binding lectinfrom rhizome of Polygonatum cyrtonema Hua. Acta biochimica et biophysica Sinica 38, 70-78). Application number 202110342884.9, invention name: The role of Polygonatum cyrtonema lectin in blocking the invasion and infection of the new coronavirus. Antiviral experiments showed that Polygonatum cyrtonema lectin protein can effectively block the infection of VERO cells by the new coronavirus. After adding mannose to block the sugar binding site of Polygonatum cyrtonema lectin protein, the antiviral ability of the protein is greatly reduced or even lost. Application number 202110323835.0, invention name: Two modified low-immunogenic Polygonatum sibiricum lectin proteins, discloses two highly active, low-immunogenic mutant Polygonatum sibiricum lectin proteins. The patent mentions that Polygonatum sibiricum lectin PCL shows very low toxicity to normal cells, has very low toxic side effects, and shows good drugability. However, as a foreign protein in the human body, Polygonatum sibiricum lectin has a certain immunogenicity. Once it enters the body, it is easy to activate the body's autoimmune response and produce neutralizing antibodies that affect the efficacy. At present, natural extracts and macromolecular drugs with anti-tumor and antiviral properties are applied to future clinical treatments, and they all face the same major problem of reducing unnecessary immunogenicity as Polygonatum sibiricum lectin PCL. This patent document discloses two modified Polygonatum sibiricum lectin proteins for anti-tumor cell proliferation.

[0005] There is currently no literature report on the use of modified Polygonatum sibiricum lectin protein for the prevention and / or treatment of coronavirus infection. Summary of the invention

[0006] The technical solution of the present invention is to provide a modified protein M4 of polygonatum sibiricum lectin, which is a highly efficient and low-immunogenic mutant of polygonatum sibiricum lectin successfully expressed by the inventors through modification of the PCL gene. The present invention also provides a preparation method and use of the modified protein M4 of polygonatum sibiricum lectin.

[0007] The present invention provides a modified protein M4 of Polygonatum cyrtonema lectin, the amino acid sequence of which is shown in SEQ ID NO:6, and the nucleotide sequence of which is shown in SEQ ID NO:10.

[0008] The modified protein M4 is prepared by analyzing the potential antigenic epitope peptides of Polygonatum cyrtonema lectin PCL under the restriction of the human leukocyte antigen complex HLA-DBR1 of the Chinese population, determining the core antigenic epitope and avoiding the amino acids in the functional domain, and then replacing the proline at position 20 of the amino acid sequence of PCL SEQ ID NO: 1 with serine, and the sequence after replacement is shown in SEQ ID NO: 6;

[0009] The present invention provides use of the polygonatum sibiricum lectin modified protein M4 in preparing a drug for preventing and / or treating coronavirus infection.

[0010] Among them, the drug is a drug that blocks SRAS-CoV-2 infection.

[0011] Among them, the SARS-CoV-2 includes original strains and mutant strains.

[0012] The present invention provides a method for preparing the modified protein M4 of Polygonatum cyrtonema lectin, which comprises the following steps:

[0013] a. Using the wild-type Polygonatum sibiricum lectin amino acid sequence SEQ ID NO: 1 as a template, the nucleic acid sequence is SEQ ID NO: 2; the amino acid at position 20 of the amino acid sequence of PCL is mutated; the RFP-g4s-M4 gene is designed and synthesized, the amino acid sequence is SEQ ID NO: 15, and the nucleic acid sequence is shown in SEQ ID NO: 20;

[0014] b. Construction of the modified Polygonatum cyrtonema lectin recombinant plasmid: insert the RFP-g4s-M4 gene into the Nde I and Hind III restriction enzyme sites of the vector pET-21 a (+);

[0015] c. Construction of a recombinant expression strain containing the RFP-g4s-M4 gene: The recombinant plasmid was transformed into the cloning bacterium DH5α to extract the plasmid, and finally transformed into the expression bacterium Rosetta-gami B (DE3) pLysS;

[0016] d. Prepare the modified protein M4 of Polygonatum cyrtonema lectin.

[0017] Wherein, the step of preparing the modified protein M4 of Polygonatum cyrtonema agglutinin described in step d is:

[0018] After inducing the expression of the fusion protein, the purified fusion protein RFP-g4s-M4 was obtained by affinity chromatography, and then the purified Polygonatum cyrtonema lectin modified protein M4 was obtained by enterokinase digestion and molecular sieve chromatography.

[0019] Specifically, the steps of preparing the modified protein M4 of Polygonatum cyrtonema lectin in step d are:

[0020] A single clone was picked and inoculated into 5 ml LB culture medium containing 15 µg / ml Kan, 100 µg / ml Amp, 34 µg / ml Cam, and 12.5 µg / ml Tet, and cultured at 37°C, 200 rpm overnight. The next day, the culture was transferred to LB medium containing Kan at a ratio of 1:100, and cultured at 37°C, 200 rpm. When the OD value reached 0.5-0.6, part of the bacterial solution was taken as a control before induction, and IPTG was added to make the final concentration 0.5 mmol / L. The culture was induced at 37°C, 200 rpm for 12 h to induce the expression of the target protein. The cells were centrifuged at 8000 rpm for 10 mins, and the cells were collected after induced expression. The cells were suspended in nickel column binding buffer (20mM PB, 500 mM NaCl, 10 mM imidazole, pH=7.4), 1 mM PMSF was added, and ultrasonication was performed at an ultrasonic power of 52 W, 3 s for ultrasonication, and 7 s, 90 times, two cycles of ultrasound, total time 30 mins. The total protein sample after ultrasound was centrifuged at 8000 rpm, 4°C for 10 mins, the supernatant protein sample was collected, and the insoluble matter was removed by filtering through a 0.22 µm filter membrane. The sample was then loaded onto the Ni 2+ -Sepharose Fast Flow affinity chromatography column. After loading the sample, wash the column with Wash Buffer to clean the unattached protein, which takes about 20 column volumes. Finally, elute with 250 mM imidazole concentration and collect the eluate. Then, use enterokinase and molecular sieve chromatography to enzymatically digest and separate the fusion protein to obtain the mutant protein, which is ultrafiltered with dd H2O and then freeze-dried.

[0021] The invention provides a pharmaceutical composition for preventing and / or treating coronavirus infection, which contains the polygonatum sibiricum lectin modified protein M4.

[0022] Compared with the protein disclosed in patent application No. 202110342884.9, the modified protein M4 of Polygonatum sibiricum lectin not only has excellent S protein binding ability and anti-new coronavirus ability, but also has significantly low immunogenicity; compared with the two modified proteins (M2 and M5) disclosed in patent application No. 202110323835.0, it has more significant activity and low immunogenicity, specifically, better coagulation activity and sugar binding activity. At the same time, it was found that the protein has the ability to resist the new coronavirus. Compared with M2, it can more efficiently bind to the key protein S protein of the new coronavirus and has better inhibitory activity; it also has lower mitogenic activity and immunogenicity, and significantly reduces the production of corresponding inflammatory factors. Compared with M5, it has the same excellent sugar binding activity, antiviral activity and low immunogenicity. However, the key difference between the two is that M4 is a mutation site designed for T cell epitopes, while the mutation of M5 is designed for B cell epitopes. Therefore, in the evaluation of immunogenicity, the changes in inflammatory factors caused by the two are different. M4 can effectively reduce the production of IFN-γ and IL-2; IL-2 is mainly synthesized by T cells after being stimulated by antigens or mitogens, and IFN-γ can upregulate MHC class II antigen presentation and enhance the peptide specificity of CD4+T cells. M5 significantly reduces the release of TNF-β and IL-4. IL-4 was once called B cell stimulating factor, which can promote the expression of MHC class II molecules by resting B cells, enhance the antigen presentation ability of B cells, enhance the expression of MHC class II, and stimulate the production of IgG and IgE. TNF-β enhances the proliferation and Ig secretion of B cells stimulated by mitogens or foreign antigens.

[0023] The present invention tested the S protein and mannan binding activity of M4 and found that it can specifically and efficiently bind to the S protein sugar chain. The results of the pseudovirus neutralization experiment showed that the modified protein can effectively block the infection of the new coronavirus on HEK293T-ACE2 cells and can effectively neutralize the new coronavirus. The immunogenicity test showed that M4 has low mitotic activity and low immunogenicity, and significantly reduces the production of antibodies and corresponding inflammatory factors.

[0024] The beneficial effects of the present invention are:

[0025] 1. The modified protein of the present invention can effectively block the infection of the novel coronavirus pseudovirus and its Delta mutant strain to HEK293T-ACE2 cells, while retaining mannose binding specificity and being able to specifically bind to high mannose. The numerous oligomannose-type, high mannose-type, and mannose-complex-type sugar chains on the surface of the novel coronavirus can be its specific targets. There is no need to consider the problems of breaking through the large number of sugar chains attached to the surface, the suppression of viral immunogenicity caused by antigen shielding, and the escape of innate / acquired immune responses, as in the development of traditional vaccines and targeted drugs. The sugar chains of glycoproteins on the surface of the virus or host cells are efficiently blocked, blocking the recognition and binding of the virus to the host cells, thereby preventing the infection of the novel coronavirus.

[0026] 2. The present invention provides theoretical and technical support for the creation of a new generation of innovative drugs with antiviral and low immunogenicity. It also provides basic research support for reducing the immunogenicity of natural drugs, reducing the toxic and side effects of macromolecular drugs, and avoiding the technical difficulties of producing a large number of neutralizing antibodies in the body, and provides a candidate for the protein to be designed as a broad-spectrum inhibitor or drug against coronavirus infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 . Isolation and purification diagram of wild Polygonatum cyrtonema lectin PCL (1: crude product; 2: sample after ammonium sulfate precipitation; 3: sample after purification by cation exchange column CM-Sepharose; 4: protein marker; 5-10: samples after purification by molecular sieve Sephacryl S-100);

[0028] Figure 2 . Changes in affinity between single-point mutant peptides and HLA after saturated mutation of V18, G19, and P20 (A. HPEPDOCK scoring results; B. Autodock Vina scoring results; box marks: original sequence amino acids; bottom letters are abbreviations of 20 amino acids);

[0029] Figure 3 . Protein stability changes after saturation mutation of V18, G19, and P20 (A. ΔΔG DynaMut calculation results; B. ΔΔS ENCoM calculation results; red triangles: dominant mutations; the letters at the bottom are the abbreviations of the 20 amino acids);

[0030] Figure 4. Obtaining diagram of recombinant protein wrPCL and mutant proteins M1-M6 (A. Affinity chromatography results after induced expression of fusion proteins. Lanes 1-6: 6 mutant fusion proteins RFP-g4s-M1 / M2 / M3 / M4 / M5 / M6; Lane 7: Fusion protein RFP-g4s-wrPCL; Lane 8: Protein Marker; B. Results of enterokinase digestion of fusion proteins. Lanes 1-5 and 7: Results of enterokinase digestion of 6 mutant fusion proteins RFP-g4s-M1 / M2 / M3 / M4 / M5 / M6, including M1-M6 and redundant protein sequences (including rfp, histidine tag, g4s, etc.) after cleavage; Lane 6: Protein Marker; Lane 8: Fusion protein RFP-g4s-wrPCL; C. Results after molecular sieve chromatography. Lanes 1-4 and lanes 6-7: 6 mutant proteins M1, M2, M3, M4, M5, M6; lane 5: ProteinMarker; lane 8: recombinant protein wrPCL; lane 9: wild-type Polygonatum cyrtonema lectin PCL);

[0031] Figure 5 . SDS-PAGE analysis of purified antibodies (M: protein marker; lanes 1-3 are PCL, M2, and M4 purified polyclonal antibodies; lanes 4-5 are wrPCL and M5 polyclonal antibodies)

[0032] Figure 6 . Potency test graph of purified antibodies (values ​​are expressed as mean ± standard deviation, n=5);

[0033] Figure 7 .Overall changes of inflammatory factors during the immune process (A. Changes in IL-2 content; B. Changes in IL-4 content; C. Changes in IFN-γ content; D. Changes in TNF-β content);

[0034] Figure 8 . PCL / wrPCL / Mutants co-cultured with BrdU to assess mitotic activity (values ​​are expressed as mean ± standard deviation, n=3);

[0035] Fig. 9 . Changes of inflammatory factors in PCL / wrPCL / Mutants co-culture (values ​​are expressed as mean ± standard deviation, n=3);

[0036] Fig.10. Dose-dependent binding of M2, M4 to S protein (fixed different concentration gradients (A) and 10, 1, 0.1µg / mL concentrations (B) of M2, M4, then incubated with 10 µg / mL concentration of S protein, and Sandwich ELISA was used to detect absorbance. Values ​​are expressed as mean ± standard deviation, n=3);

[0037] Fig.11 . Evaluation of the activity of M2, M4 against WT / Delta SARS-CoV-2 pseudovirus (values ​​are expressed as mean ± standard deviation, n=3);

[0038] Fig.12 . Activity detection diagram of recombinant mutant M1-M4 Polygonatum sibiricum lectin (A. Coagulation activity detection; B. Sugar inhibition experiment-sugar binding activity detection);

[0039] Fig.13 . ITC determination of Mannan binding to M1- M4 (the titration results of M1 (A), M2 (B), M3 (C), and M4 (D) are presented as the original ITC data (upper part) plus the corrected integrated heat of the molar ratio and the best fit function (lower part)). DETAILED DESCRIPTION

[0040] Table 1 is a description of the relevant proteins involved in the present invention.

[0041] Table 1 Abbreviations of proteins

[0042]

[0043] Example 1. Isolation and purification of PCL

[0044] Polygonatum sibiricum agglutinin ( Polygonatum Cyrtonema Lectin (PCL) protein was prepared and detected according to the method reported by the inventors (An, J. et al. Anti-HIV I / II activity and molecular cloning of a novel mannose / sialic acid-binding lectin from rhizomeofPolygonatum cyrtonema Hua. Acta biochimica et biophysica Sinica38, 70-78). The purified sample was detected by 15% SDS-PAGE. Figure 1 As shown in lanes 5-10, PCL protein was obtained.

[0045] Example 2. Determination of low immunogenic PCL mutation types

[0046] The core peptide 18-26 VGPSYRLIM of the PCL antigen epitope was determined, and the key mutation sites V18, G19, and P20 were determined through conservation analysis and calculation.

[0047] Step 1. Perform saturation mutations at the V18, G19, and P20 sites of the epitope peptide (mutated to 19 other amino acids), and use HPEPDOCK and Autodock Vina to evaluate the affinity changes between human leukocyte antigen HLA and the mutant pre-peptide / single-point mutant amino acid peptide ( Figure 2 ), identify mutations that significantly reduce binding, thereby reducing immune response and theoretically reducing protein immunogenicity. HPEPDOCK results are shown in Figure 2. Figure 2 As shown in A, the lower the score / the higher the absolute value, the bluer the color, the more stable the binding; conversely, the more the binding force decreases, that is, the higher the score / the lower the absolute value, the redder the color. Figure 2 As shown in B, the lower the score / the higher the absolute value, the greener the color, the more stable the binding; conversely, the more the binding force decreases, that is, the higher the score / the lower the absolute value, the closer the color is to orange. After analyzing and comparing the two, V18Y, V18C, G19Q, P20H, P20S and P100R were selected as target mutations to further analyze the effects of the above mutation types on the stability of PCL protein.

[0048] Step 2. Use DynaMut (Rodrigues CH, Pires DE, Ascher DB. DynaMut: predicting the impact of mutations on protein conformation, flexibility and stability. Nucleic Acids Res. 2018 Jul 2; 46(W1): W350-W355.) to calculate the effects of 57 different single-point mutations on PCL protein stability (ΔΔGDynaMut values) after saturation mutation of amino acids at V18, G19, and P20. At the same time, calculate the ΔΔS ENCoM value, that is, the effect of the change in vibrational entropy caused by the single-point mutation on protein dynamics and thermal stability. The results are shown in Figure 2. Figure 3 The calculation results of ΔΔG DynaMut are shown in Figure 3 A. The higher the score and the bluer the color, the more stable the protein is after the mutation. Conversely, the greater the decrease in stability after the mutation, the lower the score and the redder the color. Figure 3As shown in B, the higher the score and the yellower the color, the greater the vibration entropy change after mutation and the more unstable the protein; conversely, the smaller the vibration entropy change after mutation and the more stable the protein, the lower the score and the closer the color to gray. The results of ΔΔG DynaMut value and ΔΔS ENCoM value show that compared with the wild-type protein, the protein stability between different mutants varies greatly. In summary, V18Y, G19Q, P20H, P20S and P100R single-point mutations can ensure the stability of PCL protein while significantly reducing the affinity with HLA, so the above mutation sites and mutation types were selected for subsequent experiments.

[0049] Example 3. Design, construction, expression and purification of low immunogenicity modified proteins

[0050] Step 1. The wild-type Polygonatum sibiricum lectin gene sequence SEQ ID NO: 1 is used as a template, the nucleic acid sequence is SEQ ID NO: 2, the same as SEQ ID NO: 1, and the nucleic acid sequence is the same as SEQ ID NO: 2. According to the results in Example 2, the mutation sites V18Y, V18C, P20H, P20S, G19Q, and P100R are designed. The amino acid sequences after the first four mutations are as follows: SEQ ID NO: 3-6, and the amino acid sequences after the last two mutations are as follows: SEQ ID NO: 2 and SEQ ID NO: 4 in Application No. 202110323835.0. The corresponding nucleic acid sequences of the first four mutations are as follows: SEQ ID NO: 7-10, and the nucleic acid sequences of the last two mutations are as follows: SEQ ID NO: 3 and SEQ ID NO: 5 in Application No. 202110323835.0. Then, the fusion protein sequences RFP-g4s-wrPCL, RFP-g4s-M1 (V18Y), RFP-g4s-M2 (G19Q), RFP-g4s-M3 (P20H), RFP-g4s-M4 (P20S), RFP-g4s-M5 (P100R), and RFP-g4s-M6 (V18C) were designed. The amino acid sequence and nucleic acid sequence of RFP-g4s-M2 (G19Q) and RFP-g4s-M5 (P100R) fusion proteins are shown in SEQ ID NO: 6-7 and SEQ ID NO: 8-9 in application number 202110323835.0, respectively. The amino acid sequences of the remaining fusion proteins are shown in SEQ ID NO: 11-15, and the corresponding nucleotide sequences are shown in SEQ ID NO: 16-20. After codon optimization, they were synthesized by Beijing Qingke Biotechnology Co., Ltd.

[0051] Step 2. The synthesized fusion gene RFP-g4s-wrPCL / M1 / M2 / M3 / M4 / M5 / M6 was inserted into the expression vector pET21a (+) through the Nde I and Hind III restriction sites to obtain 7 expression plasmids; the recombinant plasmids were transformed into the cloning bacteria DH5α and then the plasmids were extracted and finally transformed into the expression bacteria Rosetta-gami B (DE3) pLysS. Single clones were selected and the correctness of the recombinant plasmids was identified by sequencing technology. The sequencing work was completed by Beijing Qingke Biotechnology Co., Ltd.

[0052] Step 3. Pick the clones verified correctly in the above steps and inoculate them into 5 ml LB culture medium containing 15 µg / ml Kan, 100 µg / ml Amp, 34 µg / ml Cam, and 12.5 µg / ml Tet, and culture them at 37°C and 200 rpm overnight. The next day, transfer them into LB culture medium containing Kan at a ratio of 1:100, and culture them at 37°C and 200 rpm. When the OD value reaches 0.5-0.6, add IPTG to a final concentration of 0.5 mmol / L, and culture them at 37°C and 200 rpm for 12 h to induce the expression of the target protein.

[0053] Step 4. After inducing expression, centrifuge at 8000 rpm for 10 mins, collect the cells, suspend the cells with nickel column binding buffer (20 mM PB, 500 mM NaCl, 10 mM imidazole, pH=7.4), and add PMSF to a final concentration of 1 mM. Then perform ultrasound with an ultrasound power of 52 W, which is 8% of the total power of 650 W. Ultrasound for 3 s, 7 s interval, 90 times, two cycles of ultrasound, and a total time of 30 mins. Centrifuge the total protein sample at 8000 rpm, 4°C for 10 mins, collect the supernatant protein sample, and filter through a 0.22 µm filter to remove insoluble matter. Load the filtered supernatant onto the Ni column that has been equilibrated with Binding Buffer in advance. 2+ - Sepharose Fast Flow affinity chromatography column. After loading the sample, wash the column with Wash Buffer to clean the unattached protein, which takes about 20 column volumes. Finally, elute with 250 mM imidazole concentration and collect the eluate. Wash the column with ddH2O and store it in 20% ethanol. Perform 15% SDS-PAGE identification on the purified sample to obtain the purified fusion protein ( Figure 4 .A).

[0054] Step 4. Use enterokinase to digest the purified fusion protein RFP-g4s-wrPCL / M1 / M2 / M3 / M4 / M5 / M6 in the above step to obtain the cleaved wrPCL / M1-M6 protein. The digestion results are as follows: Figure 4 .B, and the enzyme digestion reaction system is shown in Table 2. After digestion, about 31 kDa of redundant protein sequences (including rfp, histidine tag, g4s, etc.) and 11.9 kDa of target proteins wrPCL, M1-M6 were obtained.

[0055] Table 2 Enterokinase digestion reaction system

[0056] Composition volume Fusion Protein 10 µl 10x Enterokinase Lysis Buffer 5 µl Enterokinase (0.1U) diluted 10 times (add 2 µl enterokinase dilution to the control group) 2 µl Ultrapure water 33 µl Total 50 µl

[0057] Step 5. Sephacryl S-100 was used to perform gel filtration chromatography on the digested sample obtained in the above step. Physiological saline (0.9% sodium chloride solution) was used as the elution buffer. The eluted protein peak was detected by UV at OD 280, and the eluted protein with the peak was collected. The separation and purification results were detected by 15% SDS-PAGE. The results are shown in Figure 4 .C, that is, the purified target proteins wrPCL and M1-M6 were obtained, with a molecular weight of approximately 11.9 kDa.

[0058] The beneficial effects of the present invention are demonstrated below by testing the immunogenicity of the modified protein, immunomodulation and inflammatory response, binding ability with SARS-CoV-2 Spike, virus neutralization activity testing, coagulation activity, sugar inhibition activity, and affinity with mannan.

[0059] Experimental Example 1 Detection and evaluation of immunogenicity of modified proteins

[0060] Compare the differences in the strength of the corresponding immune responses triggered by different recombinant proteins during the immunization process, compare the strength of their immunogenicity, and analyze and verify whether the mutation sites designed to reduce immunogenicity based on T / B cell epitopes are effective.

[0061] Step 1. Preparation of polyclonal antibodies and antibody purification PCL, wrPCL, M2, M4, and M5 proteins with a purity of more than 90% obtained in Example 3 were used. The total protein amount of each protein was about 5 mg, and the purity met the requirement of more than 85% for antibody preparation. The animals used for antibody preparation were 2 New Zealand white rabbits / each protein, and three immunizations were performed. The antiserum titer was tested one week after each immunization. After the antiserum titer reached the standard after the third immunization, the immunized animals were killed and the antiserum was collected. The antibody was purified by Protein A affinity chromatography. The antibody purification results are shown in Figure 2. Figure 5As shown, the purity of the obtained antibodies was above 85%, about 3.0-5.0 mg.

[0062] Step 2. Detect the titer of the purified antibody by ELISA, using rabbit antibodies against PCL, wrPCL, M2, M4, and M5 as primary antibodies and Goat Anti-Rabbit IgG (H&L) Antibody [IRDye 800cw] as secondary antibodies. The optimal coating concentration (4 µg / ml) was obtained by the square array method, and the optimal secondary antibody dilution concentration was 1:120000. The titer of the prepared antibody was detected by ELISA. The titer was the highest dilution at which the sample OD / blank OD ≥2.1. The results are shown in Table 3 and Figure 6 The antibody titers of the mutants were significantly reduced, with the antibody titers of M2 and M5 being 256 K, M4 being the most significantly reduced at 128 K, and PCL and wrPCL being 512 K, respectively.

[0063] Table 3. Purified antibody titer detection

[0064]

[0065] Step 3. Detect the changes of cytoinflammatory factors in the antiserum during the three immunizations by ELISA. Rabbit IFN-γ, TNF-β, IL-2, and IL-4 detection kits were used to detect the content of corresponding cytokines in the antiserum.

[0066] Soak the ELISA plate with 1× washing solution (350 µL / well) in the kit, let it stand for 30 seconds, then discard the liquid in the well and tap the plate dry. Add each gradient standard and the diluted serum sample to be tested, 100 µL / well, and incubate at room temperature for 2 hours. After incubation, discard the liquid in the well, add 1× washing solution (350 µL / well) to wash the plate 5 times, and tap the plate dry. Add the detection antibody prepared to the working concentration to the ELISA plate, 100 µL / well, and incubate at room temperature for 2 hours. Then discard the liquid in the well, add 1× washing solution (350 µL / well) to wash the plate 5 times, and tap the plate dry. Add the enzyme conjugate prepared to the working concentration to the ELISA plate, 100 µL / well, and incubate at room temperature for 20 minutes. Then discard the liquid in the well, add 1× washing solution (350 µL / well) to wash the plate 5 times, and tap the plate dry. 10 minutes before use, restore the substrate solution to room temperature, add the substrate solution to the ELISA plate, 100 µL / well, and incubate at room temperature in the dark for 15 minutes. Then add 50 µL / well stop solution to the ELISA plate, at which time the color changes from blue to yellow, and gently shake the ELISA plate until the color is uniform. Read the light absorption value at 450 nm within 10 minutes, calculate the average OD value of the standard and sample duplicate wells, and subtract the average OD value of the blank well as the calibration OD value. The test results are as follows: Figure 7 As shown in the figure, during the three immunizations, the contents of inflammatory factors in the antisera of the M2, M4, and M5 groups were generally lower than those of the PCL group, that is, the inflammatory response caused was generally weaker than that of the PCL group. Among them, M5 significantly reduced the contents of TNF-β and IL-4 during the three immunizations. M4 significantly reduced the content of IFN-γ during the three immunizations, and both M4 and M5 significantly reduced the content of IL-2 during the three immunizations, but M4 significantly reduced the production of IL-2 after the third immunization.

[0067] Experimental Example 2. Evaluation of the mitotic activity and inflammatory factor changes of the modified protein by PBMC co-culture

[0068] The human PBMC (peripheral blood mononuclear cell) co-culture experiment to evaluate the mitotic activity and inflammatory factor changes of the modified protein is mainly used to evaluate the immunogenicity of the modified protein at the human cell level, the effect on the function of human immune cells and the induction of corresponding immune responses, especially in terms of immune regulation and inflammatory response.

[0069] Step 1. After separation and stable culture of human peripheral blood lymphocytes (PBMCs), trypsinize and resuspend in IMDM medium containing 10% FBS to prepare 2 x10 6cells / mL of cell suspension. Inoculate in 96-well plates, add 50 µL of cell suspension to each well. Use PBS to dilute PCL, wrPCL, M2, M4, and M5 at a concentration of 1000 nM in a 3-fold gradient to 8 concentrations of 1000.0, 333.3, 111.1, 37.0, 12.3, 4.1, 1.4, and 0.5 nM, and then add 50 µL of each concentration of protein solution to each well. Place in a 37°C, 5% CO2 incubator and incubate for 72 hours before adding BrdU 18 hours. Use the BrdU cell proliferation assay kit for detection, and the mitotic activity is quantified as the stimulation index, that is, the signal of the stimulated cells divided by the signal of the untreated control cells (RLU of PBMC in the treated group / RLU of PBMC in the untreated group). The results are shown in Figure 8 The mitotic activity of the mutants was lower than that of the wild-type and recombinant wild-type Polygonatum sibiricum lectin, which effectively reduced the strong mitotic activity caused by the immunogenicity of the wild-type exogenous protein. The stimulation indexes of M4 and M5 at different concentration gradients were low, and their mitotic activities were similar.

[0070] Step 2. For the detection of inflammatory factors, PCL, wrPCL, M2, M4, and M5 at a concentration of 2 µg / mL were co-cultured with PBMC for 72 hours (same as above), and the culture supernatant was collected. The expression of cytokines in the supernatant was determined using human IFN-γ, TNF-β, IL-2, and IL-4 cytokine kits (same as in Example 8). The results are as follows: Fig. 9 As shown in the figure, the mutant modified proteins can effectively reduce the release of corresponding inflammatory factors compared with PCL and wrPCL, among which M4 and M5 have more obvious effects. M4 can effectively reduce the production of IFN-γ and IL-2, while M5 can significantly reduce the release of TNF-β and IL-4. The results are similar to the overall changes in antiserum inflammatory factors during the immunization process.

[0071] Test Example 3: Elisa detects the binding ability of modified protein to SARS-CoV-2 Spike

[0072] The Elisa experiment to detect the binding ability of modified proteins to SARS-CoV-2 Spike is mainly used to prove that modified proteins with excellent sugar binding activity and low immunogenicity also have the ability to bind to the S protein, a key protein in the SARS-CoV-2 infection process, suggesting that they may competitively bind to the S protein, thereby reducing the infection ability of SARS-CoV-2.

[0073] (1) Prepare 8 gradient dilutions of test protein solutions (M2, M4) at concentrations of 10, 1, 0.1 µg / mL and 3-fold dilutions with an initial concentration of 1000 nM in 1X PBS (pH 7.4). Add 100 µl to each well and incubate overnight at 4°C to coat the sample wells of a PVC microtiter plate (Corning).

[0074] (2) Discard the coating solution and wash the microtiter plate twice by adding 200 µL of washing solution [1xPBS (pH=7.4) + 0.05% Tween-20] to each well, draining the liquid in the wells each time.

[0075] (3) Add 200 µL of blocking solution (2.5% BSA, prepared in washing solution) to each well to block the remaining protein binding sites in the coated wells and incubate at room temperature for 1 hour.

[0076] (4) Discard the liquid in the wells and wash the microtiter plate twice with 200 µL of washing buffer per well. Add 100 µL of diluted S protein (10 µg / ml) to each well and incubate at room temperature for 90 minutes.

[0077] (5) Discard the liquid in the wells and wash the microtiter plate twice with 200 µL of washing buffer per well each time. Add 100 µL of detection antibody - Spike rabbit polyclonal antibody (SinoBiological) diluted 1:5000 to each well and incubate at room temperature for 2 hours.

[0078] (6) Discard the liquid in the wells and wash the microtiter plate four times with 200 µL 1X PBS per well. Dilute the conjugated secondary antibody, goat anti-rabbit IgG H&L (HRP) (Abcam) 1:1,0000 in blocking buffer and add 100 µL of the diluted conjugated secondary antibody to each well and incubate at room temperature for 1 h.

[0079] (7) Add 100 µl of TMB colorimetric solution (Beyotime) to each well, and colorimetric development is catalyzed by horseradish peroxidase (HRP). After reacting at 37°C for 15 minutes, add TMB colorimetric stop solution (Beyotime), and measure the absorbance at 450 nm using a microplate reader (Biorad). A positive reference and a blank sample are measured for each plate. GraphPad Prism6 is used to draw the graph. The results are shown in Figure 2. Fig.10 As shown, both M2 and M4 bind to the S protein in a dose-dependent manner, but the affinity between M4 and the S protein is much stronger than that of M2.

[0080] Experimental Example 4: Neutralization Activity Detection of SARS-CoV-2 Pseudovirus

[0081] The neutralization activity detection experiment of SARS-CoV-2 pseudovirus is mainly used to prove that the modified protein with excellent sugar binding activity, low immunogenicity and efficient binding to S protein has the ability to resist SARS-CoV-2 virus.

[0082] (1) 293T cells stably transfected with ACE2 plasmid (293T-ACE2 cells) were digested with trypsin and resuspended in complete culture medium [DMEM medium (Gibco) supplemented with 0.1 µg / mL streptomycin (Thermo), 0.06 µg / mL penicillin (Thermo), and 10% w / v fetal bovine serum (ExCell Bio)] and counted, and diluted to a concentration of 1x10 5 / mL, with a density of 1×10 4 Cells / well were seeded in 96-well cell culture plates (Corning) and cultured at 37°C.

[0083] (2) Use double-free DMEM to dilute the protein samples (M2, M4) to a concentration gradient of 0.005-500µg / ml; dilute ACE2 protein with double-free DMEM to a final protein concentration of 600 µg / mL (about 4.6 µM), and filter with a 0.22 µm filter for later use. Dilute SARS-CoV-2 pseudovirus of equal titer (including the original strain and Delta mutant strain, both purchased from Genomeditech) with double-free DMEM, add 0.08 µl of pseudovirus to each well, and add 50 µl of pseudovirus-DMEM mixture to each well.

[0084] (3) The diluted pseudovirus was mixed with M2 / M4 protein at a ratio of 1:1, and the diluted pseudovirus was mixed with double-free DMEM at a ratio of 1:1 (negative control group), and incubated at 37°C for 1 h; then, the M2 / M4-pseudovirus mixture was added to HEK293T-ACE2 cells, and fresh complete DMEM medium was replaced 24 h after infection.

[0085] (4) After incubation at 37 °C for 48 h, the luciferase activity in HEK293T-ACE2 cells was measured using the One-LumiTM II Firefly Luciferase Assay Kit (Beyotime) and the values ​​were read using a fluorescence microplate reader. Finally, the neutralization curve was drawn using GraphPad Prism 6 and the half inhibitory concentration (IC 50) value. See the result Fig.11 As shown in Table 4, both M2 and M4 can effectively inhibit pseudovirus infection and effectively neutralize the new coronavirus pseudovirus and Delta mutant pseudovirus. However, there are also obvious differences in the effects. M4 has the best antiviral effect, IC 50 They were 5.041 μg / ml and 4.895 μg / ml respectively. The inhibitory effect of M2 was relatively weak, with IC50 of 24.02 μg / ml and 23.65 μg / ml respectively. The neutralization ability of the two was positively correlated with the S protein affinity results and sugar binding ability.

[0086] Table 4. M2, M4 anti-WT / Delta SARS-CoV-2 IC 50

[0087] M4 M2 <![CDATA[WT SARS-CoV-2 IC 50 (μg / ml)]]> 5.041 24.02 <![CDATA[Dleta SARS-CoV-2 IC 50 (μg / ml)]]> 4.895 23.65

[0088] Experimental Example 5: Activity Detection of Modified Protein

[0089] 1. Coagulation activity test

[0090] Fresh rabbit red blood cells (RBC) were used to detect the coagulation activity of recombinant mutant (M1-M4) Polygonatum sibiricum agglutinin. Healthy rabbit red blood cells were taken and prepared into a 2% (v / v) red blood cell suspension with normal saline. Lyophilized recombinant mutant (M1-M4) Polygonatum sibiricum agglutinin was weighed and prepared into a 1mg / ml protein solution with normal saline. The above protein samples were diluted 2-fold on a V-shaped 96-well micro serum dilution plate, with a total of 13 concentration gradients of 1000, 500, 250, 125, 62.5, 31.2, 15.6, 7.8, 3.9, 1.95, 0.98, 0.49, and 0.25 µg / ml. 25 µL of the diluted sample solution was added to each well, and then 25 µL of 2% (V / V) rabbit red blood cell suspension was added to each well, and the mixture was shaken on a micro mixer for 5 mins. All mixtures were incubated at room temperature for 2 h, and the agglutination results of all protein samples were observed under a microscope. The lowest sample concentration that produced a coagulation reaction was used to represent the agglutination activity. At the same time, the number of concentration gradients that produced a coagulation reaction for each test protein in the 13 concentration gradients was calculated to calculate the relative activity.

[0091] The results of coagulation activity test showed that ( Fig.12 .A), the agglutination activities of mutants M1-M3 were 15.6 µg / ml, 7.8 µg / ml, and 62.5 µg / ml, respectively, with relative activities of 56.4%, 66.7%, and 46.2%; the optimal agglutination activity of M4 was 1.95 µg / ml, with a relative activity of 79.5%.

[0092] 2. Sugar inhibition experiment

[0093] Take the recombinant mutant (M1-M4) Polygonatum cyrtonema lectin (1mg / ml) and dilute it 2-fold according to the coagulation activity assay. Prepare thyroglobulin, mannan, mannose, galactose, fructose, N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), fucose, and sialic acid with physiological saline to a sugar solution with a concentration of 160 mmol / L (monosaccharide) and 4 mg / ml (polysaccharide and glycoprotein). Add 25 µL of each prepared sugar solution to each well of each dilution well. After adding the sugar solution, place it in an oscillator for 10 mins, incubate it at room temperature for 2 h, and observe the agglutination results of all protein samples under a microscope. Determine the concentration of the protein sample with the lowest agglutination reaction, and determine the activity of the wild-type, recombinant, and mutant protein samples after different carbohydrate treatments. Starting from the lowest sample concentration that produces a coagulation reaction, the number of concentration gradients of each test protein that produces a coagulation reaction after adding different carbohydrates is calculated, and the relative activity of the test protein after adding different carbohydrates is expressed as a percentage. At the same time, the degree of activity change of each experimental group is analyzed based on the activity of the control group without the addition of carbohydrates, and the sugar binding specificity is compared.

[0094] The results of sugar inhibition experiments showed that ( Fig.12 .B), the agglutination activity of the recombinant mutant (M1-M4) Polygonatum sibiricum lectin decreased to varying degrees after adding different carbohydrates. The addition of Mannan significantly reduced the agglutination ability of each group. After adding Mannan, the relative coagulation activity of M1- M4 mutants was 14.3%, 12.5%, 16.7%, and 11.1%, respectively, which decreased by 85.7% (6 times), 87.5% (7 times), 83.3% (5 times), and 88.9% (8 times), respectively. Mannose also greatly reduced the agglutination activity of each group. After adding Mannose, the relative coagulation activity of M1- M4 mutants was 42.9%, 37.5%, 50.0%, and 33.3%, respectively, which decreased by 57.1% (1.3 times), 62.5% (1.7 times), 50% (1 times), and 66.7% (2 times), respectively. After adding mannose and mannan, the agglutination activity of the recombinant mutant Polygonatum sibiricum lectin was competitively inhibited, that is, each group of glycoproteins showed mannose binding specificity. Among them, M4 had the best mannan and mannose binding ability, followed by M2, and M1 and M3 were relatively weakest.

[0095] The test results of the above coagulation activity and sugar inhibition experiments indicate that there are differences in activity between the mutants belonging to stability mutations. ITC was further used to accurately determine the sugar binding ability of M1-M4.

[0096] Experimental Example 6 ITC titration of affinity between modified protein and mannan

[0097] ITC titration of the affinity between modified proteins and mannan is mainly used to determine the affinity between recombinant proteins with excellent coagulation activity and sugar binding activity and their specific binding sugars (mannose / mannan), to compare the differences in mannan binding ability between recombinant proteins, and to evaluate the activity differences of recombinant proteins.

[0098] (1) Carbohydrate specificity and thermodynamic parameters were measured using a MicroCal iTC200 isothermal titration calorimeter (GE Healthcare). Purified M1-M4 were dialyzed overnight against PBS (pH 7.4) at 4 °C and concentrated by Millipore ultrafiltration columns (Germany), and the concentrations were determined by the BCA method.

[0099] (2) Titration was performed at 25 °C. Mannan (ligand) and M1-M4 were dissolved in PBS (pH 7.4). The measurement was performed in a 200 µL microcalorimeter cell. A total of 20 injections were made. The ligand was injected every 2 minutes. The first injection was 0.4 µL, and the next 19 injections were 2 µL. The stirring rate was set to 1000 rpm. The concentration of mannan used in the titration was 1 mg / mL, and the concentration of M1-M4 was 50 µM.

[0100] (3) A control titration using ddH2O was performed to measure the heat of ligand dilution, which was then subtracted from the ligand binding thermogram. The data were fitted using MicroCal Origin 7 software according to standard procedures and plotted and tabulated. The results are shown in Fig.13 and Table 5.

[0101] The ITC test results showed that the binding ability of Mannan sugar varied greatly among the mutants. M4 had the best binding ability, with an affinity of 8.55 x 10 -6 Kd (M), M2 is relatively low at 7.519 x 10 -5 Kd (M), while M1 and M3 had poor binding ability to Mannan, with M1 being 5.35 x 10 -4 Kd (M), M3 is only 7.41 x10 -3Kd (M), the binding ability is 865 times different from that of M4.

[0102] Table 5. Thermodynamic parameters of mannan binding to M1-M4

[0103] <![CDATA[Ka(M -1 )]]> SD(±) Kd(M) KD △H △S M1 <![CDATA[1.87x10 3 ]]> <![CDATA[1.60x10 4 ]]> <![CDATA[5.35 x 10 -4 ]]> 535 μM -2935±275.60cal / mol -83.4 cal / mol / deg M2 <![CDATA[1.33x10 4 ]]> <![CDATA[6.32x10 3 ]]> <![CDATA[7.519 x 10 -5 ]]> 75.19 μM -55.02±5.72cal / mol 18.7 cal / mol / deg M3 135 456 <![CDATA[7.41 x 10 -3 ]]> 7410 μM -10600±1656cal / mol -25.8 cal / mol / deg M4 <![CDATA[1.17x10 5 ]]> <![CDATA[1.80x10 4 ]]> <![CDATA[8.55 x 10 -6 ]]> 8.55 μM -1549±82.60cal / mol 18.0cal / mol / deg

[0104] Test Examples 5 and 6 demonstrate that the modified proteins have significant advantages in coagulation activity and sugar binding ability compared with the disclosed modified proteins.

[0105] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A modified protein M4 of Polygonatum cyrtonema agglutinin, characterized in that: Its amino acid sequence is shown in SEQ ID NO:6; and its nucleotide sequence is shown in SEQ ID NO:

10.

2. Use of the modified protein M4 of Polygonatum sibiricum lectin according to claim 1 in the preparation of a drug for preventing and / or treating coronavirus infection; the drug is a drug for blocking SRAS-CoV-2 infection.

3. The use according to claim 2, characterized in that: The SARS-CoV-2 described herein is the original strain and the Delta mutant strain.

4. The method for preparing the modified protein M4 of Polygonatum cyrtonema lectin according to claim 1, characterized in that: It includes the following steps: a. Using the wild-type Polygonatum sibiricum lectin amino acid sequence SEQ ID NO: 1 as a template and the nucleic acid sequence SEQ ID NO: 2, a single mutation was performed on the amino acid at position 20 of the amino acid sequence of PCL; the RFP-g4s-M4 gene was designed and synthesized, the amino acid sequence was SEQ ID NO: 15, and the nucleic acid sequence was SEQ ID NO: 20; the single mutation was changed from P to S; b. Construction of the modified Polygonatum cyrtonema lectin recombinant plasmid: insert the RFP-g4s-M4 gene into the Nde I and Hind III restriction enzyme sites of the vector pET-21 a (+); c. Construction of a recombinant expression strain containing the RFP-g4s-M4 gene: The recombinant plasmid was transformed into the cloning bacterium DH5α to extract the plasmid, and finally transformed into the expression bacterium Rosetta-gami B (DE3) pLysS; d. Prepare the modified protein M4 of Polygonatum cyrtonema lectin.

5. The method for preparing the modified protein M4 of Polygonatum cyrtonema lectin according to claim 4, characterized in that: The steps for preparing the modified protein M4 of Polygonatum sibiricum lectin described in step d are: after inducing the expression of the fusion protein, obtaining the purified fusion protein RFP-g4s-M4 by affinity chromatography, and then obtaining the purified modified protein M4 of Polygonatum sibiricum lectin by enterokinase digestion and molecular sieve chromatography.

6. A pharmaceutical composition for preventing and / or treating SARS-CoV-2 coronavirus infection, characterized in that: The invention contains the modified protein M4 of Polygonatum cyrtonema lectin as claimed in claim 1.